Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20755340 | 0.92 | CHRM5 (0.46) | CHRM5ADRA2CACHEALDH1A1TSHR | |
| SCHEMBL20755133 | 0.89 | CHRM5 (0.50) | CHRM5ADRA2CACHEHTTL3MBTL1 | |
| SCHEMBL22663446 | 0.87 | CHRM5 (0.40) | CHRM5ADRA2CACHEALDH1A1TSHR | |
| SCHEMBL12014122 | 0.75 | CHRM5 (0.50) | CHRM5ADRA2CACHEMAPTHRH3 | |
| SCHEMBL10136548 | 0.74 | FFAR4 (0.33) | — | |
| SCHEMBL20654283 | 0.72 | HRH3 (0.38) | ALDH1A1MAPTTHRBHRH3 | |
| SCHEMBL25143750 | 0.72 | ACHE (0.32) | CHRM5ADRA2CACHE | |
| SCHEMBL14714232 | 0.71 | CHRM5 (0.46) | CHRM5ADRA2CACHEMAPT | |
| SCHEMBL21450690 | 0.71 | CHRM5 (0.59) | CHRM5ADRA2CACHEMAPTTHRB | |
| SCHEMBL31010039 | 0.71 | CHRM5 (0.59) | CHRM5ADRA2CACHEMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019036384-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |